How to read peptide evidence

“There is a study” is a starting point. To understand what that study means, identify the material, the people or experimental model, the route, the comparison and the outcome. Those details determine whether a result can answer the question you are asking.

Begin with a specific question

Compare “does this peptide work?” with “did this formulation improve walking ability in people with this condition?” The second question gives a study something concrete to answer. It also makes gaps visible: the paper may have measured a hormone concentration, used a different formulation, or enrolled a population with a different illness. The Cochrane Handbook treats these questions of population, intervention, comparison and outcome as central to interpreting applicability. Cochrane: interpreting results.

Keep the product match equally specific. An implant, an oral capsule, a topical preparation and a powder vial do not become interchangeable because a familiar ingredient name appears on each.

Recognize what the study type can contribute

Cell and animal studies help investigate mechanisms and identify questions for later research. For example, the published SLU-PP-332 work examined exercise-related effects in experimental models, including mice. This supplies a biological research lead; it does not establish a human capsule regimen. Original SLU-PP-332 study.

Early human pharmacology studies can describe exposure or biological responses under controlled conditions. A small melatonin study compared oral and intravenous exposure in healthy men. That answers a pharmacokinetic question; it does not establish treatment effectiveness for insomnia using a supplier’s injectable vial. Original melatonin pharmacokinetic study.

Randomized trials compare defined interventions in a defined setting. They still need a careful results reading. TESICO found no significant improvement in its primary clinical outcome from intravenous aviptadil in hospitalized COVID-19 respiratory failure, and the comparison stopped for futility. Calling it a “human trial” without its result would omit the point most relevant to the claim. TESICO aviptadil trial.

These descriptions are evidence types, rather than scores for how useful or safe an ingredient is. A small positive trial, a large inconclusive trial and an unpublished registration should not share one undifferentiated “clinically studied” badge.

Read the outcome, its size and its uncertainty

A change in a laboratory marker is not the same outcome as improved function, fewer symptoms or longer survival. Check what was measured, how large the difference was, and whether the estimate was precise enough to rule out substantially different effects. Also look for adverse events and the length of follow-up. A short study cannot answer every long-term question. Cochrane’s framework for useful findings tables.

Avoid reading “not statistically significant” as proof that two treatments are identical. Equally, an exploratory subgroup result should remain labelled exploratory instead of replacing the trial’s main result.

Understand what a certainty grade means

Formal GRADE assessments rate a body of evidence for a particular outcome. Their four levels are high, moderate, low and very low. Reviewers consider bias, inconsistent findings, indirect evidence, imprecise estimates and missing or selectively published results. A grade belongs with the question and the reasons behind the judgement. Cochrane’s GRADE guidance.

Descriptive labels such as “preclinical evidence” and “formulation gap” identify the material reviewed; they are not formal certainty grades. They do not claim that a formal systematic review or GRADE assessment has been completed. A source-check date likewise records an editorial check; it does not represent clinical sign-off.

Keep approval status on its own line

Clinical evidence and regulatory authorization answer related but different questions. The FDA approval record for Scenesse concerns a manufactured afamelanotide implant and a defined indication in adults with erythropoietic protoporphyria. It does not extend that authorization to every MT-1 powder bearing a related name. FDA Scenesse approval record.

A useful evidence summary leaves you with a clear statement of what was tested, what happened, how uncertain the result remains and how closely it matches the product or question in front of you.

Sources checked September 8, 2026. Educational article; no clinical sign-off or patient instructions.